Jun 19, 2026
Incyte (INCY) Stock Dips Despite Japan’s Green Light for Minjuvi in DLBCL Treatment
Incyte (INCY) stock dropped 0.78% to $98.22 as Japan approved Minjuvi for relapsed DLBCL treatment, marking the drug's second approval in the country.
The post Incyte (INCY) Stock Dips Despite Japan’s Green Light for Minjuvi in DLBCL Treatment appeared first on Blockonomi.
Source: Blockonomi →Related News
- 44 minutes ago
AST SpaceMobile (ASTS) Stock Plunges 50% — Is Now the Time to Buy?
- 45 minutes ago
Sadot (SDOT) Stock Soars 41% on $6M TradeIQ Acquisition and $200M Financing Pack...
- 52 minutes ago
Intuitive Surgical (ISRG) Stock Plunges 10% Despite Earnings Beat — Buy the Dip?
- 53 minutes ago
Semiconductor Sector Tumbles Into Bear Market as AI Optimism Fades
- 54 minutes ago
SK Hynix (SKHY) Plunges 13.7% Before Recovery — Analysts Still Project Double th...